Form D · Pharmaceuticals
Axsome Therapeutics, Inc.
New York, NY · CIK 0001579428
Offering snapshot reported May 19, 2015 · SEC filing
- Reported sold
- $2.46M Offering amount: $7.5M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- May 6, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 19, 2015 | Initial | $2,460,000 | No comparison | 14 | SEC filing |
| Jan 7, 2015 | Initial | $1,315,000 | No comparison | 4 | SEC filing |
| Sep 23, 2014 | Initial | $2,025,000 | No comparison | 12 | SEC filing |
| Oct 30, 2013 | Amendment | $3,679,000 | $2,494,000vs Jul 3, 2013 | 41 | SEC filing |
| Jul 3, 2013 | Initial | $1,185,000 | No comparison | 10 | SEC filing |
| Jun 19, 2013 | Initial | $211,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-240209
Source: Form D, filed May 19, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Herriot Tabuteau | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
45 Rockefeller Plaza, 20th Floor
New York, NY, 10111
New York, NY, 10111